For a drugmaker advancing medicines through clinical trials, time is the enemy: the longer the process takes, the more costs ...

Many people don’t know they’re eligible. | Moderna has identified a fundamental barrier to vaccination: many people don’t ...

Shares of Moderna Inc. MRNA inched 0.55% higher to $53.09 Friday, on what proved to be an all-around mixed trading session ...

Moderna is focusing on respiratory vaccines to sustain revenue streams amid COVID-19 declines. See more on MRNA stock and its ...

A WhatsApp message has earned Moderna a reprimand from the UK's Prescription Medicines Code of Practice Authority (PMCPA), ...

The biotech industry is buzzing with exciting changes, and a lot of it is thanks to one company: Moderna. Known for its COVID ...

In recent years, the biotech industry has seen a lot of exciting changes, and much of that is thanks to one company: Moderna.

Moderna shares rebound after six days of losses. Analysts mixed on stock with Strong Sell rating but potential for future growth.

Anticipated earnings release is in 16 days. A total of 2 professional analysts have given their take on this stock in the ...

Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers’ 2024 Top Employers Survey for the tenth consecutive ...

Northwestern filed a lawsuit against Moderna Wednesday alleging the company misused the University’s patented lipid ...

Nineteen companies are receiving $21.4 million total in tax incentive awards to create 1,155 new life sciences jobs in ...